A new Free Trade Agreement (FTA) between India and the European Union (EU) could limit access to cheap Indian generic drugs, PlusNews reports. According to Doctors Without Borders, the EU is pushing for data exclusivity, which means that Indian generic drug manufacturers would no longer be able to use existing studies to make cheaper, identical drugs. Currently, more than 80 percent of all donor-funded antiretroviral drugs used in developing countries are Indian generics. EU officials have said the FTA will not interfere with the Indian generics industry and they intend to follow the Trade Related Aspects of International Property, which allows countries to override intellectual property rights when public health is concerned.

To read the PlusNews article, click here.